Literature DB >> 25785545

IBRUTinib: BRUTe force against bortezomib-resistant myeloma cells.

Lingling Xian1, Carol Ann Huff, Linda M S Resar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25785545      PMCID： PMC4614695          DOI： 10.1080/15384101.2015.1022058

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  6 in total

1.  Hitting the bull's eye: targeting HMGA1 in cancer stem cells.

Authors:  Breann L Yanagisawa; Linda M S Resar
Journal:  Expert Rev Anticancer Ther       Date:  2014-01       Impact factor: 4.512

2.  Epigenetic roles of MLL oncoproteins are dependent on NF-κB.

Authors:  Hsu-Ping Kuo; Zhong Wang; Dung-Fang Lee; Masayuki Iwasaki; Jesus Duque-Afonso; Stephen H K Wong; Chiou-Hong Lin; Maria E Figueroa; Jie Su; Ihor R Lemischka; Michael L Cleary
Journal:  Cancer Cell       Date:  2013-09-19       Impact factor: 31.743

Review 3.  Overcoming bortezomib resistance in multiple myeloma.

Authors:  Megan Y Murray; Martin J Auger; Kristian M Bowles
Journal:  Biochem Soc Trans       Date:  2014-08       Impact factor: 5.407

Review 4.  The high mobility group A1 gene: transforming inflammatory signals into cancer?

Authors:  Linda M S Resar
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

5.  HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells.

Authors:  Sandeep N Shah; Leslie Cope; Weijie Poh; Amy Belton; Sujayita Roy; C Conover Talbot; Saraswati Sukumar; David L Huso; Linda M S Resar
Journal:  PLoS One       Date:  2013-05-02       Impact factor: 3.240

6.  HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis.

Authors:  Andrew Schuldenfrei; Amy Belton; Jeanne Kowalski; C Conover Talbot; Francescopaolo Di Cello; Weijie Poh; Hua-Ling Tsai; Sandeep N Shah; Tait H Huso; David L Huso; Linda M S Resar
Journal:  BMC Genomics       Date:  2011-11-04       Impact factor: 3.969
  6 in total
  1 in total

1.  Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL.

Authors:  Christian Schmidl; Gregory I Vladimer; André F Rendeiro; Susanne Schnabl; Thomas Krausgruber; Christina Taubert; Nikolaus Krall; Tea Pemovska; Mohammad Araghi; Berend Snijder; Rainer Hubmann; Anna Ringler; Kathrin Runggatscher; Dita Demirtas; Oscar Lopez de la Fuente; Martin Hilgarth; Cathrin Skrabs; Edit Porpaczy; Michaela Gruber; Gregor Hoermann; Stefan Kubicek; Philipp B Staber; Medhat Shehata; Giulio Superti-Furga; Ulrich Jäger; Christoph Bock
Journal:  Nat Chem Biol       Date:  2019-01-28       Impact factor: 15.040
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.